(Q24202101)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Huperzine A for mild cognitive impairment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

mild cognitive impairment

20 February 2020

main subject

1 reference

inferred from title

cognitive dysfunction

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2

Bi Rong Dong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Jirong Yue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Xiufang Lin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Hong Mei Wu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Taixiang Wu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

12 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

CD008827

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Donepezil for mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Donepezil for dementia due to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Review: insufficient evidence on Huperzine A for Alzheimer's

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment, amnestic type: an epidemiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Risk factors for transitions from normal to mild cognitive impairment and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Incidence and outcome of mild cognitive impairment in a population-based prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine A for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Galantamine for Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment: directions for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Alzheimer disease: progress or profit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Clinical practice. Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

A phase II trial of huperzine A in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment: conceptual basis and current nosological status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Vascular risk factors, incidence of MCI, and rates of progression to dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Alzheimer's disease and age-related memory decline (preclinical)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Involvement of M1-muscarinic acetylcholine receptors, protein kinase C and mitogen-activated protein kinase in the effect of huperzine A on secretory amyloid precursor protein-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine A for mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-alpha in intracerebroventricular beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Protective effects of huperzine A on β-amyloid25–35 induced oxidative injury in rat pheochromocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008827.PUB2

Huperzine-A in capsules and tablets for treating patients with Alzheimer disease

21 January 2018

1 reference

12 December 2020

Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging.

1 reference

12 December 2020

Classification criteria for mild cognitive impairment: a population-based validation study

1 reference

12 December 2020

Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells

1 reference

12 December 2020

Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Mild cognitive impairment

1 reference

12 December 2020

Huperzine A reverses cholinergic and monoaminergic dysfunction induced by bilateral nucleus basalis magnocellularis injection of beta-amyloid peptide (1-40) in rats

1 reference

12 December 2020

Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.

1 reference

12 December 2020

Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.

1 reference

12 December 2020

10.1002/14651858.CD008827.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23235666%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

23235666

1 reference